Alliance Wealth Advisors (Utah)’s Krystal Biotech KRYS Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$218K	Buy	+586	New	+$175K	0.04%	224

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s KRYS Position: Q2 2026 in Review

Alliance Wealth Advisors (Utah) opened a new position in Krystal Biotech (KRYS) in Q2 2026: 586 shares worth $218K. The stake represents 0.04% of the portfolio and ranks #224 among its holdings.

423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Alliance Wealth Advisors (Utah) held 586 shares of Krystal Biotech worth $218K as of Q2 2026.
Krystal Biotech was a new Alliance Wealth Advisors (Utah) position in Q2 2026.
Krystal Biotech made up 0.04% of Alliance Wealth Advisors (Utah)'s portfolio in Q2 2026, its #224 holding.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q2 2026, filed 23 Jul 2026.